News

The onset and early progression of motor and cognitive symptoms, specific by disease type to each amyotrophic lateral sclerosis (ALS) patient, are determined by age and sex, and to some extent by mutations in ALS genes, a large data study has found. The study, “ALS phenotype is influenced…

AB Science plans to launch a Phase 3 clinical trial testing the safety and effectiveness of its tyrosine kinase inhibitor masitinib as an add-on treatment for people with amyotrophic lateral sclerosis (ALS). Its announcement follows U.S. Food and Drug Administration (FDA) approval of the company’s investigational new…

First, the bad news: If you’re one of the 30 million or so Americans with a rare disease, you probably have lower immunity to the novel coronavirus than most people. Now, the good news: You already know how to face loneliness and adversity — qualities that make you far stronger…

The Muscular Dystrophy Association (MDA) is hosting an online Q&A session today to discuss the best ways that people with neuromuscular diseases might protect themselves during the COVID-19 pandemic. The 30-minute session can be accessed on the MDA’s Facebook page, and starts at 6 p.m. EST. People with…

The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because of the coronavirus disease COVID-19 pandemic. The event’s sponsor, the National Organization for Rare Disorders (NORD),…

A single brain area previously thought to control only the movement of the hands and arms also may control movement across all four limbs, a study found. This discovery opens new avenues for the use of brain-computer interfaces in people who have lost control of their arms and legs,…

People with amyotrophic lateral sclerosis (ALS) are less likely to have used anti-diabetic medications in the five years preceding their diagnosis than matched individuals of the same population, a study found, supporting an inverse association between diabetes treatments and the risk of ALS. The research also points to…

Radicava (edaravone), an approved treatment for amyotrophic lateral sclerosis (ALS), can be taken for up to one year without losing its effectiveness, and benefits patients who delay its start — say, after six months of placebo in a clinical trial, a post hoc analysis of that Phase 3…

Tikomed has secured $5.5 million in financing from investors to support the ongoing clinical development of ILB, its lead therapy candidate for degenerative neurological diseases, including amyotrophic lateral sclerosis (ALS). The funding also will help develop Ibsolvmir, a therapy to increase the effectiveness of transplanting cells to treat patients…

Target ALS and The ALS Association will jointly fund two projects focused on the development of new tests to evaluate TDP-43’s potential as a biomarker of amyotrophic lateral sclerosis (ALS). Nearly all ALS cases are characterized by the formation of toxic aggregates (clumps) containing the TDP-43 protein. These…